Search by Drug Name or NDC
NDC 50090-1301-01 Clopidogrel 75 mg/1 Details
Clopidogrel 75 mg/1
Clopidogrel is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by A-S Medication Solutions. The primary component is CLOPIDOGREL BISULFATE.
MedlinePlus Drug Summary
Clopidogrel is used alone or with aspirin to prevent serious or life-threatening problems with the heart and blood vessels in people who have had a stroke, heart attack, or severe chest pain. This includes people who have percutaneous coronary intervention (PCI; angioplasty; a type of heart surgery) that may involve inserting coronary stents (metal tubes surgically placed in clogged blood vessels to improve blood flow) or who have coronary artery bypass grafting (CABG; a type of heart surgery). Clopidogrel is also used to prevent serious or life-threatening problems with the heart and blood vessels in people who have peripheral arterial disease (poor circulation in the blood vessels that supply blood to the legs). Clopidogrel is in a class of medications called antiplatelet medications. It works by preventing platelets (a type of blood cell) from collecting and forming clots that may cause a heart attack or stroke.
Related Packages: 50090-1301-01Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Clopidogrel
Product Information
NDC | 50090-1301 |
---|---|
Product ID | 50090-1301_b68d05a1-12ae-473f-b9cb-ca80cac9e2af |
Associated GPIs | 85158020100320 |
GCN Sequence Number | n/a |
GCN Sequence Number Description | n/a |
HIC3 | n/a |
HIC3 Description | n/a |
GCN | n/a |
HICL Sequence Number | n/a |
HICL Sequence Number Description | n/a |
Brand/Generic | n/a |
Proprietary Name | Clopidogrel |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | clopidogrel bisulfate |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | TABLET, FILM COATED |
Route | ORAL |
Active Ingredient Strength | 75 |
Active Ingredient Units | mg/1 |
Substance Name | CLOPIDOGREL BISULFATE |
Labeler Name | A-S Medication Solutions |
Pharmaceutical Class | Cytochrome P450 2C8 Inhibitors [MoA], Decreased Platelet Aggregation [PE], P2Y12 Platelet Inhibitor [EPC], P2Y12 Receptor Antagonists [MoA] |
DEA Schedule | n/a |
Marketing Category | ANDA |
Application Number | ANDA076274 |
Listing Certified Through | 2024-12-31 |
Package
NDC 50090-1301-01 (50090130101)
NDC Package Code | 50090-1301-1 |
---|---|
Billing NDC | 50090130101 |
Package | 90 TABLET, FILM COATED in 1 BOTTLE (50090-1301-1) |
Marketing Start Date | 2014-11-28 |
NDC Exclude Flag | N |
Pricing Information | N/A |